

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5459025

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	ASCENDIS PHARMA GMBH	10/11/2018
RECEIVING PARTY DATA		
Name:	ASCENDIS PHARMA A/S	
Street Address:	TUBORG BOULEVARD 5	
City:	HELLERUP	
State/Country:	DENMARK	
Postal Code:	69120	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14435350
CORRESPONDENCE DATA		
Fax Number:	(212)588-0500	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	212-588-0800	
Email:	docket@haugpartners.com, smccaskey@haugpartners.com	
Correspondent Name:	HAUG PARTNERS LLP	
Address Line 1:	745 FIFTH AVENUE	
Address Line 2:	10TH FLOOR	
Address Line 4:	NEW YORK, NEW YORK 10151	
ATTORNEY DOCKET NUMBER:	514453-3993	
NAME OF SUBMITTER:	JOSEPH W. TRELOAR	
SIGNATURE:	/Joseph W. Treloar/	
DATE SIGNED:	04/04/2019	
Total Attachments: 2		
source=01886963#page1.tif		
source=01886963#page2.tif		

ASSIGNMENT

WHEREAS, Ascendis Pharma GmbH, having an address of Im Neuenheimer Feld 584, 69120 Heidelberg, Germany, (hereinafter referred to as Assignor) is the current owner by assignment of the invention described in United States Patent Application Serial No. 14/435,350 filed April 13, 2015, and of all United States Letters Patent to be obtained therefrom (hereinafter referred to as Invention);

AND WHEREAS, Ascendis Pharma A/S, having an address of Tuborg Boulevard 5, 2900, Hellerup, Denmark, (hereinafter referred to as Assignee) is desirous of acquiring the entire right, title, and interest in and to said Invention;


NOW, THEREFORE, for good and valuable consideration, the receipt for and sufficiency of which is hereby acknowledged, Assignor does hereby sell, assign, transfer, and set over unto said Assignee, and Assignee's legal representatives, successors, and assigns, the entire right, title, and interest in and to said Invention, including any continuations, continuations-in-part, divisions, reissues, re-examinations, or extensions thereof, including any and all patents of the United States and foreign countries that may be issued for said Invention;



UPON SAID CONSIDERATIONS, Assignor hereby agrees with Assignee that Assignor will not execute any writing or do any act whatsoever conflicting with these presents;

FURTHERMORE, Assignor covenants that Assignor will, at any time upon Assignee's request, without further or additional consideration but at the expense of said Assignee, execute such additional assignments and other writings and do such additional acts as said Assignee may deem necessary or desirable to perfect the Assignee's enjoyment of this grant, and will render all necessary assistance in making application for and obtaining original, divisional, continuation, continuation-in-part, reexamined, reissued, or extended Letters Patent of the United States or of any and all foreign countries on said Invention, and in enforcing any rights or causes of action accruing as a result of such applications or patents, including giving testimony in any proceedings or transactions involving such applications or patents, and executing preliminary statements and other affidavits, it being understood that the foregoing

01833934.DOCX

covenant and agreement shall bind and inure to the benefit of the assigns and legal representatives of Assignor and Assignee.

 [Assignor Representative Name] <u>JØTTE SØNDERGAARD</u>	 Signature of Witness
[Assignor Representative Title] <u>MANAGING DIRECTOR</u>	<u>ROXANA LEMNAR</u>
Ascendis Pharma GmbH	Printed Name of Witness
Date: <u>11-OCT-2018</u>	Date: <u>11-OCT-2018</u>

 [Assignee Representative Name] <u>Michael Wolff Jensen</u>	 Signature of Witness
[Assignee Representative Title] <u>Chairman Ascendis Pharma A/S</u>	<u>Henrik Bolgan Thomsen</u>
Ascendis Pharma A/S	Senior Director, Legal & Compliance Ascendis Pharma A/S
Date: <u>12-OCT-2018</u>	Printed Name of Witness
	Date: <u>12-10-2018</u>